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Norepinephrine-related mechanism in hypertension accompanying re-
nal failure. Various blood pressure (BP)-regulating factors were as-
sessed before and after 4 weeks of selective norepinephrine (NE)
inhibition with the sympathetic neurone blocker, debrisoquine, in nine
hypertensive, nine normotensive hemodialysis patients (HDP), and 11
normal subjects. On placebo, hypertensive HDP had an increased total
blood volume (P < 0.05) and exchangeable sodium (P < 0.001), while
both HDP groups had increased (P < 0.05) plasma clearances of NE
and angiotensin II (All), and tended to have higher basal plasma NE,
renin, and All levels, and lower BP responses to NE or All than normal
subjects. Plasma epinephrine and the chronotropic dose of isoprotere-
nol (CDI) did not differ significantly among groups. Debrisoquine
lowered supine BP markedly in hypertensive HDP (on average from
181/107 to 148/88 mm Hg) and slightly in normotensive HDP (143/78 to
131/76mm Hg), but not in normal subjects (116/74 to 120/79mm Hg). In
all groups, plasma NE, CDI, and NE pressor dose were reduced in
parallel (by 35 to 75%; P < 0.05 to <0.001), and the relation between
stepwise increasing plasma NE and BP changes during NE infusion was
commensurably displaced to the left (P < 0.01). The remaining param-
eters were not changed consistently. Conclusion: HDP, as normal
subjects, respond to decreased sympathetic outflow with increased
alpha- and beta-receptor sensitivity. Hypertension in HDP depends
strongly on a NE-related mechanism. The latter seems to complement
renin-angiotensin, sodium and fluid volume in the pathogenesis of high
BP.
Mécanisme relié a Ia noradrénaline de I'hypertension accompagnant
l'insufllsance rénale. Divers facteurs régulant Ia pression artérielle (BP)
ont été mesurés avant et aprés 4 semaines d'une inhibition selective de
Ia noradrCnaline (NE) par Ia débrisoquine, un bloqueur des neurones
sympathiques, chez neuf hémodialysés hypertendus et neuf hémodial-
ysés normotendus (HDP) et chez 11 sujets normaux. Avec le placebo,
les HDP hypertendus avaient une augmentation du volume sanguin
total (p < 0,05), et du sodium échangeable (p < 0,001), tandis que les
deux groupes HDP avaient des clearances plasmatiques de NE et
d'angiotensine II (All) augmentées (p < 0,05), et tendaient a avoir des
NE, des rénines, et des niveaux d'AII plasmatiques debase plus élevCs,
et des rCponses BP plus faibles a NE ou All que les sujets normaux. La
noradrénaline plasmatique, et Ia dose chronotrope d'isoprotCrCnol
(CDI) ne différaient pas significativement entre les groupes. La
dCbrisoquine a abaissC BP en position couchée de facon marquee chez
les HDP hypertendus (en moyenne de 181/107 a 148/88 mmHg) et
lCgérement chez les HDP normotendus (143/78 a 131/76 mmHg) mais
non chez les sujets normaux (116/74 a 120/79 mmHg). Dans tous les
groupes, NE plasmatique, CDI, et la dose pressive de NE étaient
diminuées en parallCle (de 35 a 75%; p <0,05 0,001) et la relation entre
une augmentation en marche d'escalier de NE plasmatique et les
modifications de BP au cours de Ia perfusion de NE Ctaient dCplacées de
facon marquee vers Ia gauche (p < 0,01). Les autres paramCtres
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n'étaient pas changes de facon consistante. Nous concluons que HDP,
comme les sujets normaux, repondent a une diminution de I'influx
sympathique par une augmentation de Ia sensibiitC des rCcepteurs
alpha et beta. L'hypertension des HDP depend fortement d'un
mécanisme liC a NE, et cela semble complCmentaire de Ia rénine et de
l'angiotensine, du sodium et du volume liquidien dans la pathogenic de
la BP Clevée.
The prevalence of hypertension increases with decreasing
kidney function and reaches about 85% at the stage of terminal
renal failure that requires dialysis treatment [1]. The mainte-
nance of a normal blood pressure (BP) requires a dynamic
equilibrium among major regulatory factors, such as the body
sodium-fluid volume state, the sympathetic and renin—angi-
otensin pressor systems, the basal vascular tone, and cardio-
vascular reactivity to vasoactive stimuli, and, perhaps, vaso-
depressor prostaglandins and kinins also [2]. Sodium-fluid vol-
ume retention and an inappropriately increased renin-angiote-
nsin activity are considered to play important complementary
roles in the pathogenesis of hypertension associated with mild
to terminal renal impairment [3, 4]. In fact, removal of excess
body sodium and/or elimination of the renal renin-angiotensin
effector axis by surgery or pharmacological inhibition may
normalize BP in most patients with end-stage kidney disease [1,
5].
Whether and to what extent the mechanisms of hypertension
in renal failure may also involve the sympathetic nervous
system or disturbances in cardiovascular responsiveness is still
unclear. Blood levels of norepinephrine (NE) and epinephrine
are normal or increased at the stage of pre-terminal renal failure
and during regular hemodialysis treatment [6—8]. However, no
consistent relationship between circulating catecholamine lev-
els and BP could be detected [6—8], while cardiovascular
responsiveness to NE even tended to be blunted in patients
with renal failure [81 and in experimental uremia [9].
A more dynamic approach, assessing BP regulation at dif-
ferent levels of sympathetic activity, could help to elucidate an
existing noradrenergic component in hypertension accompany-
ing terminal renal failure. A previous report of marked de-
creases in peripheral vascular resistance and BP after total
autonomic blockade suggested a pathogenetic contribution of
an autonomic mechanism, but did not discriminate between
noradrenergic and parasympathetic components [10]. Debriso-
quine, a postganglionic sympathetic neurone blocker, has been
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a useful tool to study the impact of selective NE inhibition on
cardiovascular regulation in essential hypertension [11, 12].
Therefore, this model was chosen to investigate whether a
NE-related mechanism participates in the maintenance of hy-
pertension in terminal renal failure. An assessment of relation-
ships among BP, pressor factors, or correlates such as plasma
NE, epinephrine, renin and angiotensin II (All) levels, ex-
changeable body sodium and blood volume, as well as cardio-
vascular responsiveness to NE, All and isoproterenol was
made in hemodialysis patients and normal subjects before and
after 4 weeks of pharmacological sympathetic inhibition.
Methods
Subjects
Three groups of subjects were studied. One group consisted
of nine chronic hemodialysis patients with high BP (three
women and six men, aged 27 to 68 years; mean age 51 13
(±sD) years). Hypertension was defined by supine BP values
consistently >160/100 mm Hg at dry wt after dialysis. Each of
these patients had left ventricular hypertrophy by electrocar-
diography and chest X-ray. When given previously,
antihypertensive drugs were discontinued 4 weeks before
study. The residual renal function, evaluated by 24-hr creati-
nine clearance, averaged 1.3 2.4 mllmin/l.73 m2. The renal
diagnosis established by clinical and laboratory criteria and/or
renal biopsy was glomerulonephritis in five, nephroangioscle-
rosis in two, and polycystic kidney disease or interstitial
nephropathy each in one patient. A group comprised of nine
chronic hemodialysis patients with a normal BP (five women
and four men, aged 21 to 69 years; mean age, 44 10 years).
Their predialysis supine BP was usually <140/90 mm Hg. 24-hr
creatinine clearance averaged 2.1 5 ml/minll .73 m2. The renal
diagnosis was interstitial nephropathy in four, polycystic kid-
ney disease in two, and glomerulonephritis in three patients.
During the period of these studies, the ultrafiltration-induced
weight change during the individual hemodialyses averaged
—2.1 1.1 kg in the hypertensive and —1.8 0.8 kg in the
normotensive dialysis group, while dry wt in these two groups
averaged 62 10 and 60 13 kg, respectively. Patients with
retinal hemorrhages or papilledema, previous stroke or myo-
cardial infarction, with congestive heart failure, aortic aneu-
rysm, or other major diseases of extra-renal organs were
excluded from study. The third group consisted of 11 normal
subjects (five women and six men, aged 24 to 62 years, mean
age 39 15 years). All were healthy volunteers with a BP
consistently <140/90 mm Hg. These normal subjects have also
served as control group in a study of patients with essential
hypertension [12]. None of the women undergoing this study
was on hormonal contraceptives.
Study design
All subjects gave their informed consent prior to the study.
The hemodialysis patients were instructed to follow the usual
diet with restricted sodium (range 17 to 36 mEq/day), potassium
(15 to 25 mEq/day), and fluid intakes. All patients underwent
the same hemodialysis program 6 hrs twice weekly. The normal
subjects were instructed to eat a normal diet, avoiding very high
or low sodium intakes [13].
Initially, a placebo, two tablets daily, was given for 4 weeks.
The placebo was then replaced by active debrisoquine given in
two daily doses during 4 weeks. The initial dose (5 mg twice
daily) was increased weekly until BP was normalized to
140/90 mm Hg (in the hypertensive patient group) or marked
side effects appeared (all study groups). On this basis, higher
doses were reached in the normal subjects than in the two
hemodialysis patient groups. During the last treatment week,
mean doses were 30 10 mg/day in the hypertensive
hemodialysis patients, 21 7 mg/day in the normotensive
hemodialysis patients, and 45 5 mg/day in the normal
subjects.
At the end of the placebo and debrisoquine treatment phases,
the following measurements were made immediately before a
regularly scheduled hemodialysis (2 days after preceding dialy-
sis) in the dialysis patients and on any suitable day in the normal
subjects. BP, heart rate (HR), exchangeable sodium (Na),
blood volume and plasma sodium, potassium, creatinine, renin
activity (PRA), NE and epinephrine levels were determined in
the morning after overnight fast and 1 hr of recumbency,
according to our standard procedure [13, 14]. BP, HR, NE and
epinephrine levels were measured again after 1 hr of being up
and about. Thereafter, the patients rested in the supine posi-
tion. A 5% dextrose solution was infused during 20 mm and an
isoproterenol sensitivity test was performed, with successive
bolus injections of 0.2, 0.4, 0.8, 1.6 j.g isoproterenol hydrochlo-
ride, as described previously [12, 15]. All blood samples were
obtained through an intravenous cannula inserted at least 30
mm before initial sampling.
One to 3 days later (in the normal subjects) or before the next
hemodialysis treatment (in the patients), NE and All were
infused intravenously as described previously from this labora-
tory [12, 16]. After overnight fasting and an equilibration period
with slow intravenous infusion of 5% dextrose in the supine
position (6 mL/hr), basal BP and HR were measured. Blood
samples were drawn from the arm contralateral to the infusion
through an indwelling intravenous cannula (inserted 30 to 60
mm previously) for determination of PRA, NE and epinephrine
levels. These basal samples were collected between 8:30 and
9:30 A.M. The dextrose solution was then replaced by an
infusion of 1-NE bitartrate in 5% dextrose, which was infused at
stepwise increasing dose rates of approximately 20, 40 and 100
ng/kg body wt/min and, when the NE-induced increase in mean
BP did not reach 20 mm Hg, at a rate of 200 ng/kg/min, during
20 mm each. During the last 10 mm of each infusion step, BP
and HR were recorded each mm. At the end of each infusion
step, blood was drawn from the arm contralateral to the
infusion for determination of plasma NE. The NE solution was
then replaced by 5% dextrose, which was infused during 45 to
50 mm at a constant rate. At the end of this second equilibration
period, basal BP and heart rate were measured, and blood was
drawn for determination of PRA and All levels. The dextrose
solution was then replaced by a solution of All (Hypertension,
Ciba, Basel, Switzerland) in 5% dextrose, which was infused at
increasing dose rates of approximately 2, 4, and 10 ng/kg/min,
and, when the All-induced increase in diastolic BP did not
reach 20 mm Hg, at a rate of 20 ng/kglmin, during 20 mm each.
BP and heart rate were monitored as described above. At the
end of each All infusion step, blood was collected for determi-
nation of plasma All levels.
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Table 1. Blood pressure and pressor factors or correlates before and after sympathetic inhibition in normal subjects and hemodialysis patients
subjects
Hemodialysis patients
Normal Normotensive Hypertensive
Placebo Debrisoquine Placebo Debrisoquine Placebo Debrisoquine
Blood pressure, mm Hg
Supine 116/74 10/11 120/79 11/9 143/78 8/9C 131/76 16/7c 181/107 9/9 148 88 8/11"
Upright 110/80 13/9 104/79 7/10 136/82 11/9 110/64 13/4" 182/108 19/9 121/78 ll/l5
Heart rate, beat/mm
Supine 61 9 55 7" 73 10" 64 7 85 7C 65 6"
Upright 85 10 80 15 85 7.5 67 41 95 6 74 8f
Body wt, kg 70.7 9.9 70.7 9.9 61 14b 62.6 14 64.8 9.7 65.4 10
Plasma
creatinine, mg/dl 0.9 0.1 0.9 0.1 13.3 2.2 13.2 2.1 11.6 2.5 11.2 1.7
sodium, mmole/liter 140 2 140 2 137 2 136 2 137 3 136 5
potassium, mmole/liter 4.1 0.5 4.3 0.3 5.0 0.7 5.1 0.4 4.7 0.8 4.6 0.7
Plasma renin activity,
ng/ml/hr
Supine 0.8 0.6 0.7 0.5 53 3.5 2.5 2.0 4.7 2.2C 1.9 1.5
Upright 2.1 1.3 3.8 3.le 5.8 3.9" 3.2 2.6 4.6 2.lC 2.4 1.9
Norepinephnne, ng/dl
Supine 24.9 12.4 12.7 4.8 31.7 10.4 21.1 18,5" 25.4 18.1 13.0 12.5"
Upright 54.8 17.2 31.3 lO.l 59.5 21.8 39.5 31.3e 48.3 30,1 25.1 l5.8e
Epinephrine, ng/dl
Supine 2.5 1.3 3.5 3.6 2.7 1.8 2.2 1.3 3.8 1.9 3.0 2.0"
Upright 5.7 3.8 4.9 2.0 3.6 2.7 2.5 1.4 5.2 3.5 4.7 2.9
Hematocrit, % 40.6 4.2 41.6 3.9 29 3C 28 4 26 3C 25 3
Blood volume, ml 4483 1121 4519 1083 4269 1080 4490 990 5420 910" 4460 1000
Exchangeable sodium,
mmole 2804 422 2955 448 2589 751 2665 734 3260 375c 3280 383
a Values are the mean SD.
b P < 0.05 vs. normal subjects.
P < 0,01 vs. normal subjects.
d P < 0.05 vs. placebo.
P < 0.01 vs. placebo.
P < 0.001 vs. placebo.
Analytical procedures
BP was measured with standard cuff and sphygmomanome-
ter; phase 5 was taken as diastolic BP, and the mean of three
readings was used for analysis. During the infusion studies, BP
was monitored with automatic recorders (Physiometric SR2,
Physiometrics International, Malibu, California, USA; or
Dynamap, Applied Medical Research Company, Tampa, Flor-
ida) and the mean of 8 to 10 measurements was used for
analysis. Mean arterial BP was calculated as the sum of the
diastolic and one-third of the pulse pressure. During the
isoproterenol sensitivity test, HR was monitored by electrocar-
diography; the resting (pre-infusion) HR was calculated as the
mean HR from 10 R-R intervals, while HR after isoproterenol
injections was calculated from the three shortest R-R intervals
after injection. Plasma sodium and potassium were measured
by flame photometer and creatinine by autoanalyzer. Plasma
and blood volume and Naex were measured by a standard
isotope dilution technique, using '25I-human serum albumin and
24Na, respectively [14]. PRA and plasma All were measured by
radioimmunoassay [17, 18], NE and epinephrine by radioenzy-
matic method [19], as reported previously from this laboratory
[12, 13]. Cardiovascular pressor responsiveness to NE or All
was assessed by blood level-BP response curves [16, 20].
Pressor doses of NE and All required to increase mean (NE
infusion) or diastolic (All infusion) BP by 20 mm Hg, were
calculated from dose-BP response curves. Total plasma clear-
ance of infused NE or All was calculated by the ratio between
the infused dose rate and concomitant variation in plasma
concentration [12, 16]. The chronotropic isoproterenol dose
was derived from the dose-response curve relating HR to
isoproterenol dose [15]; it was defined as the dose increasing
HR 25 beats/mm.
Statistical methods
Since natural logarithmic transformation rather than absolute
values followed a Gaussian distribution [12, 13], for statistical
analysis we used the natural logarithmical transformation of
PRA, All, and NE levels, doses of infused NE, All, or
isoproterenol, pressor doses of NE or All, and chronotropic
doses of isoproterenol. Statistical analysis included paired and
unpaired (two-tailed) Student t test, regression analysis, and
analysis of variance and co-variance.
Results
Blood pressure, heart rate, and some biochemical and
pressor factors before and after debrisoquine treatment
Under placebo conditions, systolic BP was significantly
higher (P <0.01) in the normotensive dialysis patients than in
the normal subjects, while both diastolic and systolic BP were
increased markedly in the hypertensive dialysis group (Table 1).
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Table 2. Cardiovascular responsiveness before and after sympathetic inhibition in normal subjects and hemodialysis patients
1n1'usions
subjects
Hemodialysis patients
Normal Normotensive Hypertensive
Placebo Debrisoquine Placebo Debrisoquine Placebo Debrisoquine
Isoproterenol
Chronotropic dose, g 2.11 2.05 1.17 0,53 1.46 0.9 0.85 0,12d 4.66 4.63 1.37 1.36e
% —45 —42 —71
Norepinephrine
Pre-infusion plasma norepineph-
rine, ng/dl 22.1 10.0 13.1 7.2e 35.6 214b 24.4 21.9" 36.2 19.5c 8.4
—41 —31 —77
Pressor dose, ng/kg/min 129 68 55 20 174 88 79 25 243 314 45 i3i% —57 —54 —82
Plasma norepinephrine clear-
ance, rn//mm/kg 68 30 72 30 89 37" 104 49" 92 38" 117 24"
Angiotensin
Pre-infusion plasma angiotensin
II, pg/mI 12 3 10 2 19.1 6.2 20.8 10.5 32.3 24 25.5 15.6
Pressordose,ng/kg/min 7.4 5.4 8.1 4.9 17.3 8 11.6 2.4" 17.8 12.8 15.8 11.1
Plasma angiotensin II clearance,
mI/mm/kg 94 13 94 16 117 48b 121 37 115 51" 119 41
a Values are the mean si.
b P < 0.05 vs. normal subjects.
P < 0.01 vs. normal subjects.
"P < 0.05 vs. placebo.
P < 0.01 vs. placebo.
fp < 0.001 vs. placebo.
Body wt and hematocrit were lower (P < 0.05 to <0.001) in
both dialysis groups than in the normal subjects, while HR was
increased in the supine position in the normotensive dialysis
patients (P < 0.05) and even more so (P < 0.001) in both body
positions in the hypertensive dialysis group. PRA was elevated
(P < 0.05 to < 0.01) in both dialysis groups; total blood volume
and Naex were increased in the hypertensive dialysis group only
(P < 0.05 and < 0.01, respectively), while plasma catechola-
mine levels did not differ significantly among the three groups.
As expected, a tendency for higher plasma potassium and lower
plasma sodium values was present in both dialysis groups.
After sympathetic inhibition with debrisoquine, supine BP
was unchanged in normal subjects, but decreased in the
normotensive (P < 0.01) and hypertensive dialysis patients (P
<0.001) (Table 1). Upright BP also was decreased significantly
in both dialysis groups (P < 0.001), but tended to fall only
slightly in the normal subjects. Compared to orthostatic varia-
tions in BP under placebo conditions, percentage postural
decreases averaged —8.6% in the normal subjects, and —16 or
—15%, respectively, in the normotensive and hypertensive
dialysis groups. Debrisoquine treatment restored supine BP to
<150/95 mm Hg in six and upright BP to <135/90 mm Hg in
seven of the nine hypertensive patients.
On debrisoquine, HR was decreased significantly in all
groups, except for upright values in the normal subjects (Table
I). Mean percentage decreases in supine and upright HR were
more pronounced in the normotensive (—12 and —21%, respec-
tively) and hypertensive dialysis patients (—19 and —22%) than
in normal subjects (—10 and —6%).
Plasma NE was decreased significantly in all three groups (P
<0.05 to <0.001). Percentage decreases in supine and upright
plasma NE averaged —49 and —43% in the normal subjects,
—33 and —34% in the normotensive dialysis group, and —51 and
—48% in the hypertensive dialysis group. Debrisoquine-induced
decreases in plasma NE did not correlate significantly with drug
dosage. Supine PRA was unchanged and upright PRA increased
(P < 0.01) during debrisoquine treatment in the normal sub-
jects; PRA tended to decrease slightly in the dialysis groups.
Body wt, plasma sodium and potassium, hematocrit, total
blood volume and Naex were not consistently modified by
debrisoquine.
Isoproterenol testing
Under placebo conditions, the mean chronotropic dose of
isoproterenol necessary to increase HR by 25 beats/mm did not
differ significantly among the three groups (Table 2). On
debrisoquine treatment, the mean chronotropic isoproterenol
dose was lowered by about 45% in normal subjects and
normotensive dialysis patients and by about 80% in hyperten-
sive dialysis patients.
Norepinephrine infusion
Plasma NE concentrations measured at the end of each
NE-infusion step correlated closely with the corresponding
infusion rates in all three groups (Fig. 1).
Compared to normal subjects, both dialysis groups studied
under placebo conditions had an increased plasma clearance of
NE, and, despite this, a tendency for higher pre-infusion plasma
NE concentrations, and a higher (P < 0.05 to < 0.01) NE-
pressor dose (Table 2); the slope of the plasma NE-pressor
response curve during NE infusion also was on average steeper
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Fig. 1. Relationship between plasma morepinephrine concentrations
and norepinephrine infusion rates in normal subjects and normotensive
or hypertensive hemodialysis patients, on placebo, and after sympa-
thetic inhibition with debrisoquine. See inset for symbols and values.
(P < 0.05) in the normotensive (23 5) and hypertensive (27
10) dialysis patients than in normal subjects (12 4) (Fig. 2).
The maximal increase in BP during NE infusion was accom-
panied by a comparable decrease in HR in the normal subjects
(mean pressure +23 7 mm Hg; HR —8 6 beats/mm
—13%) and normotensive dialysis patients (+23 4 mm Hg;
HR —11 6 beats/mm =
—15%). HR response in the hyper-
tensive dialysis group I was —10 5 beats/mm =
—11%,
although the associated rise in mean BP (+32 6 mm Hg)
tended to be greater than in the other groups.
Following debrisoquine treatment, pre-infusion plasma NE
and NE-pressor dose were lowered significantly (P < 0.05 to P
< 0.001) in all three groups, that is by —41 and —57%,
respectively, in the normal subjects, by —31 and —54% in the
normotensive dialysis patients, and by —77 and —82% in the
hypertensive dialysis group; decreases in the latter group were
significantly (P < 0.001) greater than in the two other groups
(Table 2). The plasma clearance of NE was significantly aug-
mented on debrisoquine in both dialysis groups (P < 0.05), and
this change tended to be again more pronounced in the hyper-
tensive (+ 27%) than in normotensive dialysis patients (+ 18%)
or normal subjects (+7%). The relationship between NE-
induced changes in mean BP and concomitant plasma NE
concentrations was displaced to the left in the normal subjects
(F = 9.33; P < 0.01), the normotensive dialysis patients (F =
10.10; P < 0.01), and the hypertensive dialysis patients (F =
10.88; P < 0.001) (Fig. 2); the shift in the latter group was most
pronounced. The response of HR to the increase in BP induced
by the highest NE infusion rate did not differ significantly
among the normal subjects (mean pressure +28 9 mm Hg;
HR —8 5 beats/mm = — 15%) and normotensive dialysis
patients (mean pressure +31 7 mm Hg; HR —6 3 beats/mm
= —12%), but was less (P < 0.05) in the hypertensive dialysis
patients (mean pressure +35 7 mm Hg; HR —4 2 beats/mm
= —6%).
Angiotensin II infusion
Plasma All levels measured at the end of each All infusion
step correlated closely with the corresponding infusion rates
(Fig. 3).
Under placebo conditions, mean basal (pre-infusion) plasma
All levels and All-pressor doses tended to be higher (twice or
more) in both dialysis groups than in the normal subjects,
despite an increased (P <0.05) plasma clearance of All in the
dialysis patients (Table 2). However, the relationship between
All-induced changes in diastolic BP and concomitant All
plasma levels did not differ significantly among the three groups
(Fig. 4). Moreover, pre-infusion plasma All concentrations, the
plasma All-pressor response relationship, and the plasma clear-
ance of All were unchanged following debrisoquine treatment
(Table 2, Fig. 4).
Correlations
Under placebo conditions, 1nPRA correlated inversely with
Naex in normotensive or hypertensive dialysis patients (r =
—0.84 and —0.82, respectively; P < 0.01); this trend in normal
subjects (—0.20), or relationships in all three groups between
S
818 Schohn et a!
Plasma norepinephrine, mm Hg
ng/dI
N r P<
36 0.89 0.001
Placebo A 24 0.80 0.001
o 29 0.70 0.001
• 33 0.69 0.001
Debrisoquine A 25 0.58 0.01
0.66 0.001
Normal subjects
Hemodialysis patients
0
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Fig. 2. Relationship between plasma norepinephrine concentrations
and changes in blood pressure before and uring norepinephrine infu-
sion in the three study groups, on placebo, and after sympathetic
inhibition with debrisoquine. Horizontal and vertical bars denote SE.
See inset for symbols.
Plasma angiotensin II,
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Fig. 3. Relationship between plasma angiotensin 11 concentrations and
angiotensin II infusion rates in the three study groups, on placebo, and
after sympathetic inhibition with debrisoquine. See inset for symbols
and values.
1nPRA and blood volume (r = —0.34 to —0.39) or plasma NE (r
=
—0.02 to —0.34), or between plasma NE and Nae,, (r = 0.26
to —0.36) or blood volume (r = —0.14 to —0.15) were not
statistically significant.
Under placebo conditions, mean supine BP correlated in the
hemodialysis patients or all subjects together significantly with
Naex (r = +0.74 and +0.64, respectively; P < 0.001) and the
product of Naex and InPRA (sodium-renin product, see [41) (r =
+0.69 and +0.70; P < 0.01); mean BP also correlated with
1nPRA in the hemodialysis patients (r = +0.52, P < 0.05), but
not in all subjects together. Mean BP in the dialysis patients or
all subjects did not correlate significantly with blood volume (r
= +0.05 and +0.19, respectively), or plasma NE (r = +0.13
and +0.01), and it correlated less well with the product of Naex
and ln plasma NE (r = +0.59 and +0.57; P < 0.01) than with
Naex alone (see above).
Debrisoquine-induced changes in mean supine BP did not
correlate significantly with concomitant variations in supine
plasma NE, NE-pressor dose, or any of the other measured
parameters.
Discussion
Postganglionic blockade with debrisoquine inhibits the phys-
iological release of NE from peripheral sympathetic nerve
endings [21, 22]; no influence on the adrenomedullary portion of
the sympathetic system has been found. The observation of
markedly decreased plasma NE levels and unchanged epineph-
rine values in the present or previous studies [12, 23] and an
increased ratio between the urinary excretion rates of
normetanephrine and NE in humans treated with debrisoquine
[22] are consistent with this concept. Moreover, this agent is
devoid of a neurotoxic potential [21], does not penetrate the
blood-brain barrier or modify the cerebral catecholamine con-
tent [24], has no known direct effects on other than noradrener-
gic BP-regulating mechanisms, and, in particular, does not per
se modify the sensitivity of blood vessels to NE or All [21, 25].
Based on these considerations, pharmacological intervention
with debrisoquine provided a model with which to study the
impact of selective NE inhibition on cardiovascular regulation
[12, 23]. Although the available pharmacological studies did not
include hemodialyzed animals or humans, the possibility of an
additional relevant central nervous action of debrisoquine in the
latter setting appears unlikely, since no characteristic central
nervous side effects such as sedation or depression occurred in
our dialysis patients, as noted previously in hypertensive pa-
tients with normal renal function [26, 27]. The doses of
debrisoquine, tolerated without symptomatic orthostatic hypo-
tension and/or intradialysis hypotension, were somewhat higher
in our normal subjects than in the normotensive or hypertensive
dialysis patients, final fourth week doses in the three groups
averaging 45 5, 21 7 and 30 10 mg/day, respectively. The
biological efficacy of the pharmacological intervention is evi-
dent from the distinct and significant reductions (P < 0.05 to <
0.001) in plasma NE concentrations. Decreases in supine and
upright plasma NE measured on the different study days (Table
1 and 2) averaged —44% in the normal subjects, —33% in the
normotensive and —58% in the hypertensive dialysis patients.
Blood levels of NE are determined both by the rate of overflow
from the synaptic cleft and by the rate of clearance from the
circulation. The latter tended to rise slightly on debrisoquine
treatment in dialysis patients, particularly in the hypertensive
group. The observed constellation suggests that the degree of
sympathetic inhibition achieved was at least as pronounced in
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Fig. 4. Relationship between plasma angiotensin II concentrations and
changes in blood pressure before and during angiotensin II infusion in
the three study groups, on placebo, and after sympathetic inhibition
with debrisoquine. Horizontal and vertical bars denote sE.
Plasma Angiotensin II, ng/mi
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the hypertensive dialysis patients as in the normal subjects and
slightly less in the normotensive dialysis groups.
Most important, a given reduction in circulating NE or NE
overflow was accompanied by a distinctly greater impact on BP
in the dialysis patients than in normal subjects. In fact, sympa-
thetic neurone blockade did not modify BP significantly in
normal subjects, but lowered BP markedly (P < 0.001) in the
hypertensive patients (from 181/107 mm Hg to 148/88 mm Hg in
the supine and from 182/108 to 121/78 mm Hg in the upright
position) and also slightly (P < 0.01 to < 0.001) in the
normotensive dialysis patients (from 143/78 to 131/76 mm Hg in
the supine and from 136/82 to 110/64 mm Hg in the upright
position). Moreover, when compared to orthostatic variations
in BP under placebo conditions, the percentage postural de-
crease following debrisoquine treatment was greater (P < 0.01)
in the two dialysis groups (—16 and —15%, respectively) than in
the normal subjects (—8.6%). From a clinical view point,
debrisoquine monotherapy restored supine BP to <150/95 mm
Hg in six and upright BP to <135/90 mm Hg in seven of the nine
hypertensive patients. These findings demonstrate that hyper-
tension in hemodialysis patients depends strongly on a NE-
related mechanism, and pharmacological sympathetic inhibition
is very effective in the clinical treatment of such patients.
Another index of cardiovascular function, namely HR, ap-
peared to be also more dependent on NE in our hemodialysis
patients. Thus, sympathetic neurone inhibition lowered supine
and upright HR on average 16% in normotensive and even 20% in
hypertensive patients, compared to only 8% in normal subjects.
The findings of the present study surprisingly reveal that the
normal adaptive balance between circulating NE or All and
their acute pressor effects [12, 281 may be largely unaltered in
hemodialysis patients, both in the untreated state and following
sympathetic inhibition. Under placebo conditions, plasma epi-
nephrine and NE concentrations, as well as the pressor reac-
tivity to stepwise increases in circulating NE, did not differ
significantly among our normal subjects and normotensive or
hypertensive dialysis patients, despite slightly higher mean
plasma NE values and NE-pressor doses in the dialysis groups.
In fact, a tendency for more distinctly raised plasma NE levels
and blunting of the acute NE responsiveness at the pre-dialysis
stage of renal failure seems to be at least partly restored during
hemodialysis therapy [8]. The decrease in plasma NE following
initiation of maintenance hemodialysis could possibly be due to
the increase in plasma NE clearance rates noted in this and a
previous study [29]. Moreover, following sympathetic neurone
inhibition, the reduction in plasma NE was in each of our three
study groups accompanied by a marked and seemingly com-
mensurate increase in acute cardiovascular responsiveness to
NE. This is evidenced by: a) a decrease in the NE-pressor dose
(by —57% in the normal subjects and by —54 and —82%,
respectively, in the normotensive and hypertensive dialysis
groups (P < 0.01 to,< 0.001); b) distinct shifts in the relation-
ship between pressor responses and plasma NE concentrations
before and during NE infusion (P <0.01); and c) reductions in
the chronotropic dose of isoproterenol averaging about —41%
in the normal subjects and normotensive dialysis patients and
—77% in the hypertensive dialysis group. These changes in
cardiovascular responsiveness were not due to an altered
baroreflex function. The latter, assessed by the chronotropic
response to NE-induced increases in BP, appeared to be
slightly impaired in the untreated hypertensive dialysis group,
but not modified further following sympathetic inhibition.
Supersensitivity of both alpha- and beta-receptors in re-
sponse to modest decreases in NE levels during sympatholytic
therapy has already been noted in normal humans and mild
essential hypertension [12]. In untreated hemodialysis patients,
a reduced responsiveness of beta2-receptors on lymphocytes,
alpha2-receptors on platelets, and vascular alpha1-receptors
was reported, and a post-receptor defect postulated [30]. How-
ever, our findings indicate that cardiovascular adrenergic recep-
tors, whatever their basal state in uremia may be, retain their
capability to upregulate when NE is lowered.
Considering the significantly (P <0.05) raised plasma clearance
of All and the slightly higher mean age [13] in our normotensive or
hypertensive dialysis patients as compared to the normal subjects,
the increased PRA and plasma All levels (on average twofold or
more) point to even more distinct activation of the renin-angiote-
nsin system in both dialysis groups. However, their tendency for
hyperangiotensinemia was again accompanied by a seemingly
commensurate decrease in acute pressor responsiveness to
stepwise increases in circulating All. This notion, which suggests
that vascular All receptors adapt physiologically [31] to altered
All levels in uremia, is supported by the rather similar plasma
AIl-pressor-response curves in our normal subjects and both
dialysis groups. Sympathetic inhibition, while tending to slightly
lower PRA in dialysis patients, but not in normal subjects, had no
consistent influence on circulating All and the acute plasma
AJI-pressor-response curves. It follows that neither the occur-
rence of hypertension in dialysis-treated terminal renal failure, nor
its marked improvement following NE inhibition, can be ex-
plained by changed interrelations between peripheral NE or
renin-angiotensin activity and acute cardiovascular NE or All
reactivity.
Chronic hyperangiotensinemia can raise BP by a greater
extent than is accounted for by the acute All responsiveness
[32]. This "slow" pressor mechanism has not been identified,
but could involve sodium retention, secondary hyperaldoste-
ronism, altered baroreceptor response, activation of the sym-
pathetic system, or "direct" vasoconstriction by All mediated
by intracellular factors. The concomitant pathogenetic roles of
the body sodium-blood volume state and renin-angiotensin
system in hypertension accompanying mild to terminal renal
failure are well established [3—5, 33, 34], and are again sup-
ported by the significant correlations between mean BP and
Naex and/or PRA in the present study (r =0.52 to 0.74; P < 0.05
to <0.001). Considering the excess in body sodium and blood
volume in our hypertensive, but not normotensive patients, the
normal to high PRA and All levels in the former group are
clearly inappropriate [3, 4]. On the other hand, the tendency for
increases in both plasma All and potassium predicts similarly
supernormal or high plasma aldosterone concentrations [35, 36]
in the normotensive and hypertensive dialysis groups. Altered
peripheral metabolism and diminished neural re-uptake of NE
in uremia [9, 37] limit the value of basal plasma NE concentra-
tions as an approximate correlate of overall sympathetic ner-
vous activity. Nevertheless, considering the inhibitory influ-
ence of very high sodium intake on circulating catecholamines
in normal subjects [38], somewhat lower plasma NE and
epinephrine values could be expected in our sodium-volume-
expanded hypertensive hemodialysis patients than in the non-
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expanded normotensive patients. The absence of such a differ-
ence may, therefore, be consistent with an inappropriate NE-
sodium relationship, at least in some hypertensive hemodialysis
patients. The seemingly appropriate adjustment of cardiovas-
cular receptor sensitivity to acute variations in circulating All
and NE does not mean that such hypertension in terminal renal
failure is merely a consequence of overhydration with subse-
quent whole body circulatory autoregulation [39], but with the
renin-angiotensin and sympathetic systems as innocent by-
standers. In fact, the potent antihypertensive effect of sympa-
thetic blockade, despite a persisting sodium-fluid volume ex-
cess in our hypertensive hemodialysis group, and the previ-
ously noted efficacy of All reduction or inhibition [5, 33, 401 in
some of these patients demonstrate that the sympathetic and
renin-angiotensin systems, per se or in the presence of excess
body sodium, activate an important and perhaps even common
pressor mechanism, which may be situated peripherally of their
vascular receptors. Moreover, it follows that a categorical
division of hypertension in dialysis patients into a "renin-
mediated" and a "volume-dependent" form must be regarded
as an oversimplification.
The maintenance of a homeostatic equilibrium within the
"proximal" regulatory loops containing the sympathetic and
renin-angiotensin systems and their cardiovascular receptors
would seem to be biologically reasonable. It may, in fact, be
necessary to maintain a stable BP with changes in posture or
under stress. Without appropriate receptor adaptation, the
acute increases in plasma NE and All when standing up or their
decreases when lying down could promote orthostatic hyper-
tension or hypotension, respectively, even in the presence of
supine hypertension or hypotension. These complications are
not particularly common in untreated hypertension accompa-
nying terminal renal failure, and the tendency of orthostatic
decreases in BP following sympathetic inhibition in normal
subjects and patients with essential hypertension or renal
failure may be promoted by venous pooling rather than insuf-
ficient upregulation of NE receptors [121. However, apart from
regulating their own vascular receptors, chronic changes in
circulating All or sympathetic activity in patients with terminal
renal failure can obviously also modify additional factors that
are involved in long-term BP control. Intracellular mechanisms
play a decisive role in the regulation of basal cardiovascular
muscle tone [41, 42]. Therefore, it is conceivable that, with
progressive renal failure, the development of hyperangi-
otensinemia and/or sodium retention [3, 4, 34] may alter these
"peripheral" mechanisms and basal vascular tone in a way that
the latter become also more dependent on the prevailing level of
sympathetic activity. This would explain why, in the absence of
apparent sympathetic overactivity, norepinephrine seems to
complement sodium and All as an important factor in the
maintenance of hypertension in terminal renal failure.
In addition to the observed accelerated clearance of both NE
and All from circulating blood, certain other hormones partic-
ipating in cardiovascular regulation, such as aldosterone [43]
may also be cleared more rapidly in hemodialysis patients
carrying an arteriovenous fistula. An increased transhepatic
extraction and metabolism [44, 45], secondary to the high
cardiac output state commonly occurring in the anemic
hemodialysis patients [46], could be a common contributing
mechanism. A different genesis should underly the further rise
in plasma NE clearance during sympathetic inhibition with
debrisoquine, since the latter has no effect on or even decreases
cardiac output [24, 47].
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